Avalo Therapeutics, Inc. · NASDAQ:AVTX
The Vanguard Group's stake in Avalo Therapeutics, Inc. fell to 4.43% (Schedule 13G/A)
Event Dec 31, 2025 · Filed Jan 30, 2026
The Vanguard Group's stake in Avalo Therapeutics, Inc. fell to 4.43%, 804,084 shares, as a passive investor on Dec 31, 2025. Filed Jan 30, 2026 (Schedule 13G/A).
- Stake
- 4.43%
- Shares
- 804,084
- Intent
- Passive
- What changed
- Fell below 5%
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| The Vanguard Group | 4.43% | 804,084 |
Source
Related
- Avalo Therapeutics, Inc.
- The Vanguard Group
- Avalo Therapeutics, Inc. shareholders
- Schedule 13G · The Vanguard Group · Oct 30, 2025
- Form 4 · Sullivan Christopher Ryan · Sep 18, 2026
- Form 4 · Sullivan Christopher Ryan · Sep 11, 2026
- Form 4 · Doyle Mittie · Sep 1, 2026
- Form 4 · Sullivan Christopher Ryan · Aug 19, 2026
- Form 4 · Doyle Mittie · Aug 19, 2026